In about 3% to 5% of patients with NSCLC MET alterations are presented that can drastically change a patient's prognosis. Now, an investigational MET inhibitor called tepotinib was granted a breakthrough designation by the FDA, and it may prove beneficial for patients in this space.
While treatment options for lung cancer have vastly improved over the last decade, attitudes toward the disease have actually gotten worse.
Targeted therapies for patients with EGFR-mutated and HER2-positive NSCLC have yet to see widespread success, but these 3 novel therapies, presented at the 2019 World Conference on Lung Cancer, show promise for this patient population.
The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.
Patients with METex14-Mutated NSCLC potentially have a new first-line treatment to look towards as Capmatinib has been granted a breakthrough designation by the FDA.
Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.
Two different randomized clinical trials not only validated the value of annual lung cancer screening in patients, but also can open the doors for vital smoking cessation talks.
The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.
While the treatment landscape for lung cancer continues to grow, nurses must stay up-to-date on the most recent advances and approvals across each subgroup of patients.
From long-term data to additional clinical trials, more is needed to better understand immunotherapy in lung cancer.
One expert discusses the arrival of immunotherapy, as well as other exciting advances, for the treatment of patients with small cell lung cancer.
Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.
Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.
Immunotherapy has drastically changed the treatment landscape for non-small cell lung cancer, but how can practitioners decide who should get frontline chemotherapy, too?
Selective inhibitors for patients with non–small cell lung cancer with rare oncogenic drivers are showing high response rates in clinical trials, explained one expert.
When it comes to molecular testing to advance the field of lung cancer, coordinated efforts between providers—and institutions nationwide—are key.
The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Personalized treatments are drastically improving the outcomes of patients with non-small cell lung cancer, but there is still work to be done when it comes to understanding drug resistance.
Oncology nurses shouldn’t be concerned if patients with non-small cell lung cancer experience skin toxic effects after immunotherapy.
Patients with higher tumor mutational burdens tended to be more likely to be depressed, according to recent research.
The FDA approved pembrolizumab (Keytruda) for patients with advanced small cell lung cancer (SCLC) who experienced disease progression after 2 or more prior lines of therapy.
Patients with lung cancer often report feelings of stigma, and different approaches to care than in other cancer settings.
Broader clinical trial criteria could nearly double the number of patients with advanced non-small cell lung cancer who are eligible to participate.
Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.
In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.
